AbbVie reported a Phase 3 win for its multiple myeloma bispecific etentamig (T cell engager), saying the therapy met the main endpoint by improving progression or survival versus standard regimens. The company positioned the result alongside a safety profile characterized by low rates of serious immune responses, aiming for broader use in community oncology settings rather than intensive monitoring models used for some earlier bispecific therapies.